Baxter Showcases Multiple Innovative Solutions at CIIE, Reinforcing Commitment to Smart Healthcare

Shanghai, China, November 2022 – Today, Baxter International Inc. (“Baxter”), a global leader in diversified medical technology, made its debut at the 5th China International Import Expo (CIIE). The company comprehensively showcased its global innovations and localized practices across various treatment scenarios, including smart operating rooms, smart intensive care units (ICUs), and smart dialysis. Baxter also launched several new products for the first time, fully demonstrating its commitment to empowering smart healthcare and meeting the comprehensive needs of Chinese patients through innovative, high-quality medical products and services.

Baxter Unveils Multiple Innovations at CIIE for the First Time, Doubling Down on Smart Healthcare

Xu Runhong, President of Baxter Healthcare’s Greater China region, stated, “The China International Import Expo (CIIE) is a vital platform for global cooperation, exchange, and shared opportunities. This year, we are honored to leverage the CIIE to globally launch and showcase Baxter’s innovative achievements and smart healthcare scenarios. We will continue to apply our cross-disciplinary expertise and digital pioneering practices, working hand in hand with all stakeholders to explore every innovative possibility in our mission to ‘save and sustain lives,’ thereby creating opportunities for a better tomorrow for patients.”

Baxter’s portfolio of innovative solutions spans diverse areas, including end-stage renal disease, acute and critical care, medication infusion, and medical nursing, thereby meeting the varied needs of healthcare in China. Baxter is accelerating the availability of more innovative healthcare solutions to local patients, delivering higher-quality and more efficient medical services.

This year, Baxter will leverage the platform of the China International Import Expo (CIIE) toGlobal Debut and First Exhibition: ROTURM Electric Anti-Pressure Ulcer MattressThis innovative product, developed with extensive involvement from the Baxter China team, is a tailored solution designed for Chinese ICUs based on standard ICU daily care protocols. It will comprehensively support the intelligent upgrade of critical and emergency care in China. Integrating key features such as Continuous Lateral Rotation Therapy (CLRT), assisted turning, and the Microclimate Management MCM® air circulation system, it works in conjunction with standard ICU bed mattresses to prevent and treat pulmonary complications and pressure ulcers caused by prolonged bed rest in ICU patients. This can improve patient outcomes and reduce overall medical costs. Furthermore, it alleviates healthcare staff from strenuous daily physical tasks, enhances the efficiency of nursing human resources, and thereby contributes to the advancement of critical care standards and the high-quality development of hospitals.

In recent years, Continuous Renal Replacement Therapy (hereinafter referred to as CRRT) has developed rapidly, playing a vital role in the treatment of acute and chronic renal failure and in saving the lives of critically ill patients. Among these advancements, ready-to-use CRRT replacement fluids are an indispensable component of CRRT treatment. At this year’s China International Import Expo,Baxter’s Three New Ready-to-Use Continuous Renal Replacement Therapy (CRRT) Replacement Solutions Make Their China Debut。These three CRRT replacement fluids feature striking innovations in technology and formulation, better meeting the needs of personalized clinical treatment. All three come in large 5L volumes, with two utilizing dual-chamber bag packaging technology and an innovative “ready-to-use” design that reduces the burden of manual preparation. As an effective, reliable, balanced, and convenient combination of replacement fluids, they provide patients with a comprehensive, higher-quality CRRT treatment solution. All three “ready-to-use” replacement fluids have been included in Baxter’s local production plan, which will further empower high-quality products and a more efficient, high-standard localized operational service system, serving critically ill patients undergoing CRRT therapy and supporting ICU healthcare professionals in their diagnostic and treatment efforts.

Hemodialysis is a critical method for treating end-stage renal failure. As one of the leaders in the treatment and management of end-stage renal disease (ESRD), Baxter brought to this year’s China International Import ExpoTheranovaChina Debut. Theranova is used for innovative Expanded Hemodialysis (HDx), which extends the clearance range of uremic toxins and achieves toxin removal efficacy comparable to or even superior to that of hemodiafiltration, without the use of replacement fluid. HDx offers simpler operation and greater cost-effectiveness, making it an innovative blood purification model well-suited to China’s specific healthcare context.

Baxter is not only accelerating the delivery of cutting-edge innovative technologies and products to patients and healthcare providers in China, but also actively exploring intelligent connectivity in medical scenarios. This initiative aims to further optimize patients’ quality of life and demonstrate new possibilities for enhancing the efficiency of healthcare resources. At this year’s China International Import Expo (CIIE), Baxter’s smart healthcare solutions fully showcased the synergistic effects of its innovations, empowering smart healthcare experiences and helping improve medical efficiency by addressing the needs of both patients and healthcare professionals.

For example, the “Smart Home” component of Baxter’s Smart Dialysis scenario leverages digital technologies and accompanying services to extend high-quality medical resources into communities and households, thereby providing robust support for home-based peritoneal dialysis among patients with end-stage renal disease (ESRD). Furthermore, Baxter is actively exploring additional smart healthcare scenarios, such as Smart ICUs and Smart Operating Rooms, to develop intelligent optimization solutions for clinical diagnosis, treatment, and nursing care. These initiatives aim to streamline medical workflows and comprehensively enhance healthcare efficiency. Looking ahead, Baxter will deepen the implementation of smart connectivity across the entire healthcare landscape, creating significant opportunities to optimize comprehensive patient benefits and save and sustain lives.

To deepen its development in China, Baxter has established a full-lifecycle industrial chain in the country, covering research and development (R&D), intelligent manufacturing, supply, and services. Its one R&D center and seven production bases invested and laid out in China have become important hubs for introducing technologies into China and exporting them to the Asia-Pacific region. More importantly, by independently coordinating these key links locally, Baxter is able to keenly discern trends in China’s healthcare services, cater to the more diverse needs of Chinese patients, and provide more flexible and human-centric medical solutions.

Baxter will also take a more proactive approach to leveraging the CIIE’s impact, working hand in hand with government agencies, healthcare institutions, industry associations, and other partners to advance the development of disease management systems and innovate care delivery models. By continuously raising industry standards and expanding the value of healthcare services in China, Baxter aims to bring cutting-edge technologies and products closer to Chinese patients, collaborating with all sectors of society to drive the development and upgrading of China’s healthcare industry.

To discover more exciting content, you are welcome to visit the Baxter Healthcare booth at the CIIE—Booth 8.1B1-05 in the Medical Devices and Pharmaceuticals & Healthcare Zone.

Every day, Baxter provides a leading portfolio of products in critical care, renal care, parenteral nutrition, and hospital and surgical products to millions of patients and healthcare professionals, supporting their treatment in home, hospital, and other settings. For nearly a century, the company has remained at the key intersection of innovation and healthcare professionals, actively fulfilling its mission to “save and sustain lives.” With products, digital health solutions, and therapies available in more than 100 countries, Baxter’s global employees leverage the company’s deep expertise and breakthroughs in the medical field to continuously drive next-generation medical innovation and transformation.

With over 30 years of development in China, Baxter has consistently adhered to a highly localized strategy and established a comprehensive industry chain spanning research and development, manufacturing, sales, and services. Baxter China is dedicated to key initiatives such as elevating medical standards, expanding healthcare accessibility, and giving back to society, making meaningful contributions to the lives and quality of life of Chinese patients while supporting the sustainable development of China’s healthcare sector.